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Abstract: Cellular factor XIII (cFXIII, FXIII-A2), a transglutaminase, has been demonstrated in a few
cell types. Its main function is to cross-link proteins by isopeptide bonds. Here, we investigated the
presence of cFXIII in cells of human cornea. Tissue sections of the cornea were immunostained for
FXIII-A in combination with staining for CD34 antigen or isopeptide cross-links. Isolated corneal
keratocytes were also evaluated by immunofluorescent microscopy and flow cytometry. FXIII-A in
the corneal stroma was quantified by Western blotting. FXIII-A mRNA was detected by RT-qPCR.
The cornea of FXIII-A-deficient patients was evaluated by cornea topography. FXIII-A was detected in
68 ± 13% of CD34+ keratocytes. Their distribution in the corneal stroma was unequal; they were most
abundant in the subepithelial tertile. cFXIII was of cytoplasmic localization. In the stroma, 3.64 ng
cFXIII/mg protein was measured. The synthesis of cFXIII by keratocytes was confirmed by RT-qPCR.
Isopeptide cross-links were detected above, but not within the corneal stroma. Slight abnormality of
the cornea was detected in six out of nine FXIII-A-deficient patients. The presence of cFXIII in human
keratocytes was established for the first time. cFXIII might be involved in maintaining the stability of
the cornea and in the corneal wound healing process.
Int. J. Mol. Sci. 2019, 20, 5963; doi:10.3390/ijms20235963 www.mdpi.com/journal/ijms
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1. Introduction
The transglutaminase (TG) family consists of nine members, eight of which blood coagulation
factor XIII (FXIII) and TGs 1-7 are enzymatically active, while the enzymatically non-active erythrocyte
band 4.2 protein also belongs to this group on the basis of structural similarity. TGs in their enzymatically
active form (protein-glutamine:amine γ-glutamyltransferase; EC2.3.2.13) catalyze an acyl transfer
reaction in which the carboxamide group of a peptide bound glutamine residue is the acyl donor and
a primary amine is the acyl acceptor. If the primary amine happens to be the ε-amino group of a
peptide bound lysine residue, the end result is the crosslinking of peptide chains by ε(γ-glutamyl)lysyl
isopeptide bond. Although the sequential similarity among TGs is modest, their secondary structure
is strikingly similar. All members of the TG family, including erythrocyte band 4.2 protein, contain
an N-terminal β-sandwich domain, a central core domain with the active site, and two C-terminal
β-barrel domains (for further details see references [1–5].)
FXIII is a unique TG, it is a coagulation factor present in the plasma playing an essential role
in maintaining hemostasis by cross-linking and thereby stabilizing the fibrin clot. As opposed to
all other TGs, plasma FXIII (pFXIII) is of tetrameric structure; it consists of two potentially active
protransglutaminase A subunits (FXIII-A2) and two inhibitory/protective non-enzymatic B subunits
(FXIII-B2). pFXIII becomes transformed into an active TG in the terminal phase of the coagulation
cascade. Thrombin cleaves off a 36-mer peptide from the N-terminus of FXIII-A, then in the presence
of Ca2+, the dissociation of FXIII-B relieves the inhibitory effect. In addition to being, the potentially
active component of pFXIII, FXIII-A2 is also a cellular enzyme (cFXIII) present in a number of cell
types. cFXIII was first discovered in platelets [6,7]; it amounts to 3% of the total platelet proteins [8].
cFXIII in resting platelets is of cytoplasmic localization [9,10], however activation by strong stimuli,
like thrombin+collagen, can translocate part of it to the platelet surface [11]. In subsequent studies
cFXIII was also demonstrated in monocytes/macrophages [12–14], in cells of mineralized tissue, i.e., in
osteoblasts, osteoclasts, osteocytes [15,16], and most recently, in preadipocytes [17].
The occurrence of TGs in the eye was investigated by Raghunath et al. who detected FXIII in the
endothelium of arterioles and capillaries in the conjunctival stroma [18]. In this study, the presence
of cFXIII in the cornea was not explored. The human cornea proteome has been analyzed, and 3250
Swiss-Prot annotated proteins were identified by LC-MS/MS technique, among them a small amount of
FXIII-A [19]. However, neither its distribution in the cornea nor its (intra)cellular localization has been
explored. In a previous study, we investigated FXIII subunits in human tears in relation to penetrating
keratoplasty [20]. FXIII-A concentration normalized for protein concentration increased 17-fold 24 h
after the surgery. This finding raised the possibility that the extra cFXIII in the tears, at least in part,
derived from the injured cornea, and prompted us to perform a comprehensive analysis of corneal
cells for the presence and distribution of FXIII-A.
2. Results
2.1. Detection of FXIII-A in the Corneal Tissue by Immunohistochemistry and Western Blotting
The presence of FXIII-A in the cornea was first demonstrated by immunohistochemistry (Figure 1).
Cells stained with an antibody specific for FXIII-A were abundant in the corneal stroma but absent in the
epithelium (upper part of the section). In the cross-section of the cornea, FXIII-A-positive cells appear as
elongated fusiform cells. No FXIII-B was detected in the cornea (not shown). The immunohistochemical
finding was confirmed by Western blotting (Figure 2A). By quantitative densitometry, 3.64 (range:
2.69–4.47) ng FXIII-A/mg corneal protein was measured (Figure 2B).
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Figure 1. FXIII-A containing cells in the cross-section of the cornea at higher and lower (insert) 
magnification. FXIII-A-positive cells are shown in green. The section was counterstained by DAPI to 
demonstrate cell nuclei. Bars represent 10 μm. 
 
Figure 2. Detection and quantification of FXIII-A in the human cornea by Western blotting. (A) 
Demonstration of FXIII-A on the Western blot of cornea lysate. (B) Quantitative densitometric 
analysis of Western blots using FXIII-A standards and four different dilutions of a cornea lysate 
containing 3.5, 7, 14, and 28 μg corneal protein. The second-order polynomial equation that 
adequately describes the calibration curve is shown on the upper part of the figure. 
Figure 1. FXIII-A containing cells in the cross-section of the cornea at higher and lower (insert)
magnification. FXIII-A-positive cells r s i r en. The section was counterstained by DAPI to
demonstrate cell nuclei. Bars represe t µ .
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Figure 2. Detection and quantification of FXIII-A in the human cornea by Western blotting.
(A) Demonstration of FXIII-A on the Western blot of cornea lysate. (B) Quantitative densitometric
analysis of W ste n blots using FXIII-A standards and fo r differe t dilution of a cornea lysate
containi g 3.5, 7, 14, and 28 µg c rneal protein. The sec n -order polynomial equation that adequately
describes the calibration curve is shown on the upper part of the figure.
2.2. The istribution of FXIII-A-Positive Keratocytes i the Corneal Stroma
Figure 3A demonstrates that keratocytes labeled for CD34 were present throughout the corneal
stroma. The mean cell count/visual field was 119 ± 5, 116 ± 6, and 115 ± 9 in the anterior, middle,
and posterior tertile of the stroma, respectively. In contrast, FXIII-A-positive cells were more abundant
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in the anterior tertile of the stroma (Figure 3B). Their occurrence gradually decreased from the anterior to
the posterior stroma, 120 ± 10, 72 ± 10, and 38 ± 6 cells/visual field were counted in the anterior, middle,
and posterior tertile. Endothelial and epithelial cells lack FXIII-A. The overlay of the two staining
patterns suggests that FXIII-A-positive cells are CD34 positive keratocytes (Figure 3C). This became even
more evident when individual keratocytes enlarged from the cross-sectional picture were investigated
for CD34 (Figure 3D) and FXIII-A (Figure 3E) positivity. The overlay picture of individual cells
confirmed that the two antigens are in the same cells (Figure 3F), however, the separation of the green
and red staining patterns suggest that CD34 and FXIII-A are located in different cell compartments.
2.3. FXIII-A Protein and FXIII-A mRNA in Isolated Keratocytes
Subsequently, individual keratocytes, isolated from the cornea lysate, were analyzed by
immunostaining and flow cytometry. Their capacity for producing FXIII-A specific mRNA was
also evaluated. In situ cornea keratocytes are large flat cells among collagen lamellae of the stroma
and possess multiple contacts with neighboring cells [21,22]. In the cross-section of the cornea,
they appeared as thin elongated cells. Isolated cells, however, lose their contact during the isolation
procedure and their cytospin preparation showed rounded shape (Figure 4). The different location of
CD34 and FXIII-A becomes evident by double immunofluorescence investigation (Figure 4A). CD34 is
a membrane protein, while cFXIII is of cytoplasmic localization. The demonstration of FXIII-A mRNA
by RT-qPCR in keratocytes (Figure 4B) strongly suggests that these cells are capable of synthesizing
their own FXIII-A proteins.
2.4. Characterization of Isolated Corneal Keratocytes by Flow Cytometry
Quantitative determination of FXIII-A containing cells among isolated keratocytes was carried
out by flow cytometry. As shown in Figure 5, the great majority of nucleated corneal cells was positive
for CD34, i.e., they represented keratocytes [23]. Approximately two-thirds of keratocytes were also
stained for FXIII-A. This result is in accordance with the immunohistochemical finding and reveals
that two populations of keratocytes (FXIII-A+ and FXIII-A-) exist in the human cornea.
Int. J. Mol. Sci. 2019, 20, 5963 5 of 17Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 4 of 18 
 
 
Figure 3. The distribution of CD34 positive keratocytes (A) and FXIII-A-positive cells (B) and their appearance in overlay picture (C) in a cornea section. In the 
lower part of the figure, two individual keratocytes were selected from the cross-section and shown at higher magnification. CD34 and FXIII-A positivity appear in 
red and green (D and E), respectively. The overlay picture (F) indicates their different distribution within the cell (DAPI labeled nuclei appear in blue). The scale 
bars represent 100 μm in A–C and 10 μm in D–F. 
Figure 3. The distribution of CD34 positive keratocytes (A) and FXIII-A-positive cells (B) and their appearance in overlay picture (C) in a cornea section. In the lower
part of the figure, two individual keratocytes were selected from the cross-section and shown at higher magnification. CD34 and FXIII-A positivity appear in red and
green (D,E), respectively. The overlay picture (F) indicates their different distribution within the cell (DAPI labeled nuclei appear in blue). The scale bars represent 100
µm in A–C and 10 µm in D–F.
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Figure 4. The presence of FXIII-A protein and mRNA in keratocytes isolated from human cornea. (A) 
In the upper part from left to right an isolated keratocyte stained for CD34 (red), FXIII-A (green), and 
the merged picture is shown (cell nucleus stained with DAPI appear in blue). CD34 appeared as a 
membrane protein, while FXIII-A is of cytoplasmic localization. Bar represents 10 μm. (B) Detection 
and quantitation of FXIII-A mRNA in keratocyte lysate by RT-qPCR. Left panel: Fluorescence 
acquired at each cycle is used for detection and quantification. NTC: No-template control; cornea: 
Technical replicate of one sample. Right panel: Standard curve on which quantification cycle was 
plotted against the log copy number of cDNA input. 
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Figure 4. The presence of FXIII-A protein and mRNA in keratocytes isolated from human cornea.
(A) In the upper part from left to right an isolated keratocyte stained for CD34 (red), FXIII-A (green),
and the merged picture is shown (cell nucleus stained with DAPI appear in blue). CD34 appeared as a
membrane protein, while FXIII-A is of cytoplasmic localization. Bar represents 10 µm. (B) Detection
and quantitation of FXIII-A mRNA in keratocyte lysate by RT-qPCR. Left panel: Fluorescence acquired
at each cycle is used for detection and quantification. NTC: No-template control; cornea: Technical
replicate of one sample. Right panel: Standard curve on which quantification cycle was plotted against
the log copy number of cDNA input.
2.5. Immunohistochemical Detection and Localization of Isopeptide Protein Cross-Links in the Cornea
The most general product of activated FXIII, just like that of most other TGs, is the cross-linking of
proteins through ε(γ-glutamyl)lysyl isopeptide bonds. A specific antibody can reveal the localization
of such bonds in tissue sections. In the cornea, this antibody did not stain the corneal stroma,
but isopeptide bonds were revealed above the anterior stroma, very likely in part of the Bowman layer
and the lower part of the epithelium (Figure 6).
Int. J. Mol. Sci. 2019, 20, 5963 7 of 17
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 18 
 
 
Figure 5. Flow cytometric analysis of isolated keratocytes. Nucleated particles were identified by 
Syto40 staining and they were characterized by staining for CD34 and FXIII-A. (A) The left panel 
shows a representative dot plot of CD34+ and FXIII+ cells prepared from a single cornea. (B) The 
right panel demonstrates the results obtained for cells from five individual cornea preparations. The 
contribution of CD34+ keratocytes to the total corneal cells and the frequency of FXIII-A+ cells in the 
keratocyte population were calculated. 
2.5. Immunohistochemical Detection and Localization of Isopeptide Protein Cross-Links in the Cornea 
The most general product of activated FXIII, just like that of most other TGs, is the cross-linking 
of proteins through ε(γ-glutamyl)lysyl isopeptide bonds. A specific antibody can reveal the 
localization of such bonds in tissue sections. In the cornea, this antibody did not stain the corneal 
stroma, but isopeptide bonds were revealed above the anterior stroma, very likely in part of the 
Bowman layer and the lower part of the epithelium (Figure 6). 
Figure 5. Flow cytometric analysis of isolated keratocytes. Nucleated particles were identified by
Syto40 staining and they were characterized by staining for CD34 and FXIII-A. (A) The left panel shows
a representative dot plot of CD34+ and FXIII+ cells prepared from a single cornea. (B) The right panel
demonstrates the results obtained for cells from five individual cornea preparations. The contribution
of CD34+ keratocytes to the total corneal cells and the frequency of FXIII-A+ cells in the keratocyte
population were calculated.
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Comprehensive ophthalmological investigations were carried out to explore the presence of
corneal abnormality in FXIII-A-deficient patients. One patient had cataracts on one eye, which caused
slightly blurred vision (corrected distance visual acuity = 0.8), all other eyes had a visual acuity of
at least 1.0. Slit lamp biomicroscopy showed no overt sign of keratoconus. Ultrasound and optical
coherence tomography examinations excluded any rough ophthalmic diseases. Six out of nine patients
had inferior steepening and asymmetric bow-tie pattern on the topographic picture on both eyes and
7 out of 18 eyes had abnormal inferior-superior diopter asymmetry (Table 1, Figure 7). One out of
18 eyes had astigmia higher than 1.5 D (patient 8). All other investigated parameters (central corneal
power, skew of radial axis, corneal thickness at the thinnest point of the cornea, whether the thinnest
point of cornea is outside of the central 2 mm, pachymetric difference between in the thinnest point
and central average, back elevation) were in the range that would not raise suspicion for keratoconus.
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i l (right eye of patient 1 in Table 1), (B) sym etrical bow-tie shape (left ey of patient 1),
(C,D) asymmetric bow-tie shape (right and left eye of patient 4). The numbers on the central part of the
pictures show the keratometric values, the circles in white and black represent the size of the pupils.
The pictures were taken by Tomey Casia anterior segment optical coherence tomography.
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Table 1. Cornea parameters of FXIII-A-deficient patients.
Pts Age Gender Mutations
Inferior-Superior Diopter Asymmetry
Inferior Steepening,
Asymmetric Bow-Tie
Pattern by Topography
OD OS OD OS
1 60 F IVS5(-1) G>A 0.0 0.4 − −
2 62 M IVS5(-1) G>A 0.4 0.8 − −
3 20 M p.R662Y 0.4 0.2 + +
4 55 F p.R662S 1.5 2.6 + +
5 57 F * 1.8 0.2 − −
6 36 F p.M159R 0.7 1.0 + +
7 60 M p.M159Rp.R661X 1.9 1.4 + +
8 22 M p.R382Sp.Q400X 1.4 1.3 + +
9 18 M IVS5 (-1) G>A 0.5 0.6 + +
Measurements and observations on the right (OD) and left (OS) eye are shown separately. Pts: Patients, F: Female, M: Male. −, + without and with cornea irregularity, respectively.
* Patient 5 is the sister of patient 4, genetic investigation only identified the lacking domain. Bold setting indicates data that could raise the suspicion for keratoconus.
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3. Discussion
cFXIII is expressed in a few cell types, however its functions have been only partially explored.
The potentially active subunit of pFXIII very likely derives from intracellular sources. Platelet FXIII
could contribute to pFXIII [24], but most recently, resident macrophages have been identified as the
major source of circulating FXIII-A [25]. In addition to being a source of pFXIII, cFXIII may exert
its effect both in the intra- and extracellular compartment. For the latter, it needs to be released
from the cells or to be translocated to the outer surface of the membrane. FXIII-A lacks the signal
sequence and asparagine-linked glycosylation; consequently, it cannot be released through the classical
secretory pathway. Although there is evidence that it can enter the alternative secretory pathway [26],
as yet no direct proof has been provided on its release from the intracellular compartment by such a
mechanism. Another way for the extracellular appearance of cFXIII is the translocation to the outer
membrane surface of activated cells or the formation of cFXIII containing microparticles leaving the
cells. The surface exposure of FXIII-A on cultured cells [16,17,27–29] and on activated platelets [11] has
been demonstrated and microparticles released by activated platelets also contain cFXIII [30].
Obviously, cFXIII might also have functions in the intracellular compartment, although some
of these functions are hard to separate from those exerted by the surface exposed molecule.
The involvement of cFXIII in platelet spreading on fibrinogen as well as on collagen I-coated surfaces
has been clearly demonstrated [31,32]. Although during platelet activation cFXIII becomes an active
transglutaminase and cross-links contractile proteins [33–36], reports on its involvement in clot retraction
are controversial and normal retraction could be elicited by FXIII-A-deficient platelets [37]. The impaired
receptor mediated and non-receptor mediated phagocytosis by FXIII-A-deficient monocytes indicate
that FXIII-A is involved in the mechanism of this monocyte function [38]. cFXIII is involved in
the hypertrophic differentiation of chondrocytes [39] and contributes to the formation of calcium
precipitates in the matrix of cultured cells [40]. In cooperation with other TGs, it contributes to the
regulation of osteoclast differentiation [41]. cFXIII is also present in osteoblasts and osteocytes [42,43].
It was suggested that together with TG1 and TG2, cFXIII is a novel regulator of bone mass [44].
However, normal bone deposition was demonstrated in mice deficient both in FXIII-A and TG2 [45].
A more recent intriguing finding on the role of cFXIII concerns its presence in mouse preadipocytes
and the demonstration that it acts as a negative regulator of adipogenesis as well as a promoter of
preadipocyte proliferation [17]. More detailed accounts on the multiple roles of cFXIII and other TGs
are provided in reviews [15,46–49].
In this study, the presence of FXIII-A in the cornea was confirmed both by immunohistochemistry
and Western blotting. Neither the epithelium nor the endothelium showed FXIII-A positivity, while in
the stroma, FXIII-A expressing cells were abundant. The contribution of FXIII-A to the total stromal
protein is low, in the ng FXIII-A/mg corneal protein range. However, considering the overwhelming
presence of collagen in the corneal stroma, this is not surprising. The detection of FXIII-A mRNA in the
corneal cells clearly showed that FXIII-A is not coming from external sources; it is synthesized in situ.
As demonstrated both by immunohistochemistry on corneal sections and by flow cytometry, FXIII-A+
cells also stained for CD34, a keratocyte marker [23]. Keratocytes represent the majority of stromal
cells and by producing collagen and glycosaminoglycans they maintain the integrity of this layer [50].
Two-thirds of CD34+ cells were also positive for FXIII-A. Although the distribution of CD34+ cells
was continuous in the corneal stroma, FXIII-A+ keratocytes tended to occur more frequently in the
anterior part. For the time being, it is not clear if the two phenotypes of keratocytes (CD34+/FXIII-A-
and CD34+/FXIII-A+) represent cell populations with functional differences.
Concerning the function of cFXIII and cFXIII+ keratocytes in the cornea only suggestions can
be offered. cFXIII might exert its effect both in the intracellular and extracellular compartments.
In isolated keratocytes, cFXIII was of cytoplasmic localization and, for the time being, it is not clear
if it can be secreted or exposed to the surface. The main function of active pFXIII is to cross-link
proteins. To explore such function in the cornea immunofluorescent staining of cornea sections with
an antibody that specifically reacts with isopeptide bonds were performed. No protein cross-linking
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was detected in the stroma, which is not surprising because cross-linking of stromal proteins might
impair corneal transparency. A layer of intensive staining for isopeptide bonds was detected in the
lower part of or underneath the epithelium; the latter might include the Bowman layer. Such a layer of
cross-linked proteins might be associated with the high mechanical stiffness of the Bowman layer and
important for conferring structural stability to the cornea [51]. Such cross-linked substrate could also
provide the niche for the transformation of limbal epithelial stem cells into differentiated epithelial
cells [51]. It is interesting that the gradient of stiffness from the anterior (stiffer) to the posterior stroma
(softer) [51] is similar to the differential distribution of cFXIII-positive keratocytes, however for the
time being, no causal explanation can be offered. It is also an open question whether cFXIII present in
stromal keratocytes could be released and by diffusing to the epithelial border could contribute to the
cross-linked protein layer. Our first attempt to explore this possibility was to investigate the corneal
topography of FXIII-A-deficient patients. No gross abnormality of the cornea was found in either of
the patients. Slight irregularity, suggesting weakening of the cornea structure, was detected in six out
of nine patients. The significance of this finding is unclear. However, it reminds us of the situation
of impaired wound healing of FXIII-A-deficient patients. Only a fraction of these patients presented
impaired wound healing [52,53], while in FXIII-A knock out mice, delayed and irregular healing of
excisional wound was clearly manifested [54]. Evidently, keeping the structural integrity of the cornea,
just like wound healing, is a complex process with multiple players, one of which could be cFXIII.
Perhaps the investigations should be extended to other TGs. TGs, like TG1, TG2, and TG3, might also
play a role in the formation of cross-linked corneal structures and in the structural stabilization of
the cornea.
In this study, only quiescent keratocytes were investigated. We believe that our results open
up a new area of investigation on the involvement of cFXIII in corneal pathology. In pathological
conditions, like injury or infection, transdifferentiated keratocyte showed drastic changes: They
became capable of proliferation and migration, they produced adhesive proteins, and expressed
contractile myofibroblast character [22]. cFXIII might be involved in these changes, and it would
also be interesting to explore if FXIII+ and FXIII- keratocytes behave differently. The role of cFXIII
in corneal wound healing seems to be a particularly promising topic. Cultured corneal epithelial
stem cells proliferated and formed colonies in fibrin gel cross-linked by plasma FXIII present in
cryoprecipitate [55]. Dardik et al. demonstrated that a considerable amount of FXIIIa injected into
the cornea exhibited a proangiogenic activity and induced vascularization [56]. It is well possible
that in the case of corneal injury, involving the stroma, keratocyte cFXIII becomes externalized and
depending on its concentration, improves the healing process or, at a higher concentration, is involved
in the process of undesired vascularization. In our former study, it was shown that after penetrating
keratoplasty, patients who developed neovascularization of donor cornea had considerably higher pre-
and post-surgery FXIII levels in tears than patients with non-neovascularized cornea [20].
The results presented above clearly demonstrate cFXIII in part of CD34+ corneal keratocytes.
These cells are capable of synthesizing cFXIII and they are concentrated in the anterior corneal stroma.
They might be involved in the formation of an isopeptide-rich layer below and in the lower part of
epithelium and also could contribute to the structural stability of the cornea. The results open up
new directions in the cornea research, part of which we have started pursuing. The presence and
cellular localization of other TGs and their relationship to the isopeptide-rich protein layer is also
of considerable interest. Extension of the studies to the limbal region could also provide important
pieces of information. Experiments with isolated keratocytes could shed lite on intracellular trafficking,
mechanism of extracellular release of cFXIII, etc. Understanding the mechanism of corneal wound
healing could also profit from studying the involvement of cFXIII containing keratocytes in this process.
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4. Materials and Method
4.1. Cornea Samples
Sixteen corneas from nine donors (age 43–85 years, mean: 62.7) were used for the investigations.
Two cornea samples were obtained from eyes enucleated due to retrobulbar melanoma. The corneas
were removed immediately after enucleation. Other cornea samples were obtained from cadavers.
For the inclusion of the latter cornea samples in the study, the same criteria were used as for corneas
removed for corneal transplantation. The cornea samples were removed within 12 h of biological death.
The cause of death was neoplasm without cerebral metastasis in five cases and ischemic heart disease in
two cases. None of them suffered any kind of eye disease, HIV, hepatitis B and C, or bacterial infection.
A history of former eye surgery was also an exclusion criterion. Ethical permission for the study of
cornea samples was obtained from the Regional Ethics Committee of the Medical Faculty, University
of Debrecen, Hungary, and approved by the Office of the Chief Medical Officer for Hungary, Budapest.
4.2. FXIII Deficient Patients
Two Hungarian, five Finnish, and two Swiss FXIII-A-deficient patients (4 females, 5 males,
age 18–63) were recruited for non-invasive ophthalmological examinations (visual acuity, slit lamp
examination, corneal topography, ultrasound, and optical coherence tomography). The investigations
were approved by the respective national ethics committees, by the Office of the Chief Medical Officer
for Hungary, by the Research Ethics Committee of the Faculty of Medicine, University of Helsinki,
Finland and by the Kantonale Ethikkommission, Bern, Switzerland. FXIII-A-deficient patients who
underwent noninvasive ophthalmological investigations gave informed consent. The diagnosis of
severe FXIII-A deficiency was established by measurement of FXIII activity in patients’ plasma and
confirmed by identifying the mutations in the F13A1 gene. All patients had causative mutations,
in homozygous or in double heterozygous form (see details in Table 1). At the time of investigation,
FXIII-A-deficient patients were on prophylaxis using plasma-derived FXIII concentrate (Fibrogammin
P/Cluvot, CLS Behring, Marburg, Germany) for the Finnish and the Swiss patients or recombinant
FXIII-A2 (Novothirteen, Novo Nordisk A/S, Bagsvaerd, Denmark) for the Hungarian patients.
4.3. Immunohistochemistry
Cornea samples for immunohistochemistry were embedded in Shandon Cryomatrix freezing
medium (Thermo Scientific, Waltham, MA, USA) and stored at−80 ◦C. Frozen sections (7µm) were fixed
with acetone and incubated with normal human serum diluted 6-fold in PBS to prevent non-specific
IgG binding. Then, sections were incubated with one of the following antibodies: Monoclonal mouse
antibody against FXIII-A produced in our laboratory [8], polyclonal rabbit anti-FXIII-A (Dade Behring,
Marburg, Germany), or polyclonal rabbit anti-FXIII-B (Sigma, St. Louis, MO, USA). Immune-labeling
was visualized by either FITC-labeled anti-mouse or FITC-labeled anti-rabbit antibodies produced
in goat (Vector Labs, Burlingame, CA, USA). For double labeling immunoreactions, slides were first
incubated with rabbit anti-human FXIII-A antibody, then with FITC conjugated goat anti-rabbit IgG.
CD34 antigen was detected by incubation with monoclonal anti-human CD34 antibody (Abcam,
Cambridge, UK). The reaction was visualized by biotinylated horse anti-mouse IgG (Vector Labs)
followed by Texas Red-labeled streptavidin (Vector Labs). For the labeling of isopeptide bonds, IgM
type mouse monoclonal antibody from Covalab (Villeurbanne, France) was used and visualized by
Alexa Fluor 488 conjugated goat anti-mouse IgM antibody (Abcam, Cambridge, UK). In this case,
counterstaining for FXIII-A was carried out with Texas Red conjugated goat anti-rabbit antibody
(Vector Labs, Burlingame, CA, USA). Vectashield mounting medium with DAPI (Vector Labs) was
used for mounting slides, to counterstain nuclei and avoid bleaching fluorescence. All reactions were
carried out at room temperature; phosphate buffered saline was used for the dilution of antibodies
and in washing steps. For negative controls, the primary antibodies were replaced by the respective
non-immune control sera.
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Slides were investigated with an Axioplan fluorescence microscope (Carl Zeiss Obekochen,
Germany) equipped with selective filters and connected to CCD IMAC camera (Sony, Tokyo, Japan)
plus ISIS fluorescent imaging system (Metasystems, Altlussheim, Germany). Representative images
were acquired by confocal laser scanning microscope (LSM 700, Zeiss Oberkochen, Germany) equipped
with Plan-Apochromat 63x/1.40 oil objective and solid-state lasers. Separation of the fluorescence
signals was performed by selective laser excitation (405 nm, 488 nm, 555 nm laser lines) coupled to
efficient splitting of the emission using variable secondary dichroic beam-splitter.
4.4. Western Blotting
Epithelium and endothelium were removed by blunt knife; the remaining stroma was cut
into small pieces and transferred into SDS PAGE sample buffer containing 8 M urea. The samples
were homogenized by sonication, then denatured in boiling water for 5 min, and finally subjected
to continuous shaking for 2 days. After centrifugation, the total protein concentration of the
supernatant was measured by BCA protein assay kit (Pierce, Rockford, IL, USA). After reduction
by 5% 2-mercaptoethanol, the denatured proteins were separated by SDS PAGE (7.5% gel)
and electro-transferred to PVDF membrane. FXIII-A was detected by affinity purified sheep
anti-FXIII-A antibody (Affinity Biologicals, Ancaster, Canada) followed by biotinylated anti-sheep
IgG and avidin-biotinylated peroxidase complex (components of Vectastain ABC kit; Vector Labs).
The immunoreaction was visualized by enhanced chemiluminescence detection (ECL Plus+, Amersham,
Little Chalfont, UK) according to the manufacturer’s instructions. Biotinylated SDS PAGE standard
(Bio-Rad, Hercules, CA, USA) was used for the estimation of molecular mass. The amount of FXIII-A
in the lysate of corneal stroma was determined by quantitative densitometric analysis of the Western
blot. A standard curve was created using different concentrations of highly purified FXIII-A2 [57].
In the case of each cornea sample, determinations were carried out in quadruplicate using 4 different
dilutions. The differences between individual results were less than 6%. The mean and the range of
the results obtained from 3 cornea samples were calculated.
4.5. Isolation of Keratocytes from the Cornea and Their Immunofluorescent Analysis
Five de-epithelized and de-endothelized corneas were used for keratocyte preparation. Each cornea
was inserted into 500 µL Hank’s Balanced Salt Solution 1x (Gibco, Carlsbad, CA, USA) containing 2 mg
Collagenase I (Gibco) and incubated for 4 h at 37 ◦C under constant agitation. Cytospin preparations of
the cells were used for double immunofluorescent analysis. After fixation with 20% acetone, staining
for FXIII-A and CD 34 was carried out as described for tissue sections.
4.6. Detection and Quantification of FXIII-A mRNA in Keratocytes
Total RNA was prepared from keratocytes isolated from four corneas using High Pure RNA Tissue
Kit (Roche, Mannheim, Germany). Reverse transcription was performed on 50 ng of the isolated total
RNA in 20 µL by Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the manufacturer’s
instructions. For the detection and analytical evaluation of FXIII-A mRNA by real-time RT-qPCR,
specific PCR amplicon of the gene was used as standard. A 116 base-pair fragment was amplified using
5′-TCACGAGCGTTCACCTGTTC-3′ forward primer and 5′-CTGCACATAGAAAGACTGCCC-3′
reverse primer with 60 ◦C annealing temperature. Specific PCR products were separated by 1% agarose
gel electrophoresis, excised, and purified (High Pure PCR Cleanup Micro Kit; Roche). The concentration
of the purified nucleic acid was calculated by measuring the absorbance at 260 nm and converted into
copies per microliter [58]. Tenfold serial dilutions of the quantified FXIII-A amplicons (range: 10–105
copies/µL) were used as external standards for the FXIII-A real-time PCR reaction. The calibration
curve used for FXIII-A amplicon number calculation was created by plotting the quantification cycle
(Cq) corresponding to each standard versus the value of the respective log number of FXIII-A amplicon
concentration. PCR efficiency was determined using four serial 2-fold dilution points; Cq(s) were
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plotted versus the logarithm of dilution [59]. Efficiency for used primer pair was 112%. SPUD assay
demonstrated absence of inhibition in each qPCR reaction [60].
4.7. Flow Cytometric Analysis of Isolated Keratocytes
Cells from the lysed cornea were pelleted by centrifugation and resuspended in phosphate buffered
saline (PBS). Keratocytes suspensions were counted in Bürker chamber and also analyzed on Sysmex
XN-350 L hematology analyzer (Sysmex Europe GmbH, Germany). Cell counts of 106–107 could
repeatedly be harvested by the previously described isolation procedure. In a typical experimental
setting, we stained 105 cells for flow cytometric analysis.
Staining was carried out in the dark at room temperature. First, cells were incubated with
antiCD34-PerCPCy5.5 antibody (Becton Dickinson Pharmingen, San Jose, CA, USA) for 20 min. After
this surface staining, cells were immediately fixed by IntraStain A solution (Dako, Glostrup, Denmark)
for 15 min. Subsequently, cells were washed once in PBS and resuspended in IntraStain B solution
and simultaneously stained by FITC conjugated anti FXIII-A antibody or with FITC-conjugated
non-immune mouse IgG for 20 min. Upon completion, cells were washed once in PBS and stored in
1% paraformaldehyde. Immediately before flow cytometric analysis, cell nuclei were stained by Syto
40 (Invitrogen TM, Thermo Fischer Scientific, Rockford, IL, USA).
4.8. Non-Invasive Ophthalmological Examinations
Each FXIII patient underwent comprehensive ophthalmologic examination, including a review of
their medical history, uncorrected and corrected distance visual acuity measured by decimal notation,
manifest refraction, slit lamp biomicroscopy, fundus examination with a +90D non-contact lens,
ultrasound, and corneal topography. Tomographic parameters such as parameters from the front
and back cornea were measured in 4 cases by Pentacam (OCULUS Gmbh, Wetzlar, Germany), and in
5 cases by Tomey Casia 2 (TOMEY Corp, Nagoya, Japan). Parameters retained for the analysis were
keratometry readings; topographic astigmatism and asphericity for the anterior and posterior corneal
surfaces; pachymetry; topometric indices; and data from corneal thickness spatial profiles. Corneal
thickness is defined as the thinnest point in the corneal thickness map. Belin–Ambrosio-enhanced
ectasia display was also used in the case of Pentacam investigations. For elevation data measurement,
the best-fit sphere served as a reference body using the float option; the diameter of the reference
surface was 8 mm. The following abnormal parameters were considered as suspicious for keratoconus:
Central corneal power > 47.2 D, inferior–superior diopter asymmetry >1.2, simulated keratometry
astigmia > 1.5 D, skew of radial axis >21◦, difference between the thinnest and median corneal thickness
> 63 µm, corneal thickness on the thinnest point of the cornea < 492 µm, and thinnest point of cornea is
out of the central 2 mm area [61,62].
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Abbreviations
Cq quantification cycle
FXIII blood coagulation factor XIII
FXIII-A FXIII A subunit
FXIII-B FXIII B subunit
cFXIII cellular FXIII
pFXIII plasma FXIII
PBS phosphate buffered saline
TG transglutaminase
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